Angiotensin-converting enzyme inhibitors

Hypertension: Principles and Practice

Volumn , Issue , 2005, Pages 475-498

  Sica, Domenic A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 49449114058     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (207)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. J Am Med Assoc 2003; 289:2560-2572.
2. Sica DA, Gehr TWB. Angiotensin converting enzyme inhibitors. In: Oparil S, Weber M, eds. Hypertension: A Companion to the Kidney. 1st ed. Philadelphia: W.B. Saunders, 2000:599-608.
3. Sica DA, Gehr TWB, Frishman WH. The renin- angiotensin axis: angiotensin converting enzyme inhibitors and angiotensin-receptor blockers. In: Frishman W, Sonnenblick S, Sica DA, eds. Cardiovascular Pharmacotherapeutics. 2nd ed. McGraw-Hill, 2003:131-156.
4. Warner GT, Perry CM. Ramipril: a review of its use in the prevention of cardiovascular outcomes. Drugs 2002; 62:1381-1405.
5. White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. Pharmacotherapy 1998; 18:588-599.
6. Dickstein K, Till AE, Aarsland T, Tjelta K, Abrahamsen AM, Kristianson K, Gomez HJ, Gregg H, Hichens M. The pharmacokinetics of enalapril in hospitalized patients with congestive heart failure. Br J Clin Pharmacol 1987; 23:403-410.
7. Lapenna D, De Gioia S, Ciofani G, Daniele F, Cuccurullo F. Captopril has no significant scavenging antioxidant activity in human plasma in vitro or in vivo. Br J Clin Pharmacol 1996; 42:451-456.
8. Chalmers D, Whitehead A, Lawson DH. Postmarketing surveillance of captopril for hypertension. Br J Clin Pharmacol 1992; 34:215-223.
9. Sica DA. Angiotensin converting enzyme inhibitors: fosinopril. In: Messerli F, ed. Cardiovascular Drug Therapy. 2nd ed. Philadelphia: W.B. Saunders, 1996:801-809.
10. Brockmeier D. Tight binding influencing the future of pharmacokinetics. Meth Find Exp Clin Pharmacol 1998; 20:505-516.
11. Reid JL. From kinetics to dynamics: are there differences between ACE inhibitors? Eur Heart J 1997; 18(suppl E):E14-E18.
12. Hoyer J, Schulte K-L, Lenz T. Clinical pharmacokinetics of angiotensin converting enzyme inhibitors in renal failure. Clin Pharmacokinet 1993; 24:230-254.
13. Dzau VJ, Bernstein K, Celermajer D, Cohen J, Dahlof B, Deanfield J, Diez J, Drexler H, Ferrari R, van Gilst W, Hansson L, Hornig B, Husain A, Johnston C, Lazar H, Lonn E, Luscher T, Mancini J, Mimran A, Pepine C, Rabelink T, Remme W, Ruilope L, Ruzicka M, Schunkert H, Swedberg K, Unger T, Vaughan D, Weber M. Working Group on Tissue Angiotensinconverting enzyme, International Society of Cardiovascular Pharmacotherapy. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 2001; 88(suppl 9):1L-20L.
14. Ebihara A, Fujimura A. Metabolites of antihypertensive drugs. An updated review of their clinical pharmacokinetic and therapeutic implications. Clin Pharmacokinet 1991; 21:331-343.
15. Hui KK, Duchin KL, Kripalani KJ, Chan D, Kramer PK, Yanagawa N. Pharmacokinetics of fosinopril in patients with various degrees of renal function. Clin Pharmacol Ther 1991; 49:457-467.
16. Danielson B, Querin S, LaRochelle P, Sultan E, Mouren M, Bryce T, Stepniewski JP, Lenfant B. Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2 mg to patients with chronic renal failure and healthy control subjects. J Cardiovasc Pharmacol 1994; 23(suppl 4):S50-S59.
17. Brunner-La Rocca HP, Weilenmann D, Kiowski W, Maly FE, Follath F. Plasma levels of enalaprilat in chronic therapy of heart failure: relationship to adverse events. J Pharmacol Exp Ther 1999; 289:565-571.
18. Brown NJ, Vaughn DE. Angiotensin-converting enzyme inhibitors. Circulation 1998; 97:1411-1420.
19. Johnston CI, Fabris B, Yamada H, Mendelsohn FA, Cubela R, Sivell D, Jackson B. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertens 1989; 7(suppl):S11-S16.
20. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
21. Leonetti G, Cuspidi C. Choosing the right ACE inhibitor. A guide to selection. Drugs 1995; 49:516-535.
22. Zeitz CJ, Campbell DJ, Horowitz JD. Myocardial uptake and biochemical and hemodynamic effects of ACE inhibitors in humans. Hypertension 2003; 41:482-487.
23. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med 2003; 349:2224-2232.
24. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
25. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456-1462.
26. Sica DA. The HOPE Study: ACE inhibitors-are their benefits a class effect or do individual agents differ? Curr Opin Nephrol Hypertens 2001; 10:597-601.
27. Segura J, Christiansen H, Campo C, Ruilope LM. How to titrate ACE inhibitors and angiotensin receptor blockers in renal patients: according to blood pressure or proteinuria? Curr Hypertens Rep 2003; 5:426-429.
28. Tang WH, Vagelos RH, Yee YG, Benedict CR, Willson K, Liss CL, Fowler MB. Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 2002; 39:70-78.
29. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryden L, Thygesen K, Uretsky BF. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100:2312-2318.
30. Massie B. Neurohormonal blockade in chronic heart failure. How much is enough? can there be too much? J Am Coll Cardiol 2002; 39:79-82.
31. Tang WH, Vagelos RH, Yee YG, Benedict CR, Willson K, Liss CL, Fowler MB. Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 2002; 39:70-78.
32. van Veldhuisen DJ, Genth-Zotz S, Brouwer J, Boomsma F, Netzer T, Man In ‘T Veld AJ, Pinto YM, Lie KI, Crijns HJ. High versus low-dose ACE inhibition in chronic heart failure. A double-blind, placebo-controlled study of imidapril. J Am Coll Cardiol 1998; 32:1811-1818.
33. Carretero OA, Scicli AG. The kallikrein-kinin system as a regulator of cardiovascular and renal function. In:Brenner BM, Laragh JH, eds. Hypertension: Pathophysiology, Diagnosis, and Management. 2nd ed. New York:Raven Press Ltd., 1995:983-999.
34. Urata H. Nishimura H, Ganten D. Chymase-dependent angiotensin II forming system in humans. Am J Hypertens 1996; 9:277-284.
35. Petrie MC, Padmanabhan N, McDonald JE, Hillier C, Connell JM, McMurray JJ. Angiotensin converting enzyme and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol 2001; 37:1056-1061.
36. Ennezat PV, Berlowitz M, Sonnenblick EH, Le Jemtel TH. Therapeutic implications of escape from angiotensinconverting enzyme inhibition in patients with chronic heart failure. Curr Cardiol Rep 2000; 2:258-262.
37. Mooser V, Nussberger J, Juillerat L, Burnier M, Waeber B, Bidiville J, Pauly N, Brunner HR. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 1990; 15:276-282.
38. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990; 82:1730-1736.
39. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998; 339:1285-1292.
40. Tom B, Dendorfer A, Danser AH. Bradykinin, angiotensin (1-7), and ACE inhibitors: how do they interact? Int J Biochem Cell Biol 2003; 35:792-801.
41. Rodriguez-Garcia JL, Villa E, Serrano M, Gallardo J, Garcia-Robles R. Prostacyclin: its pathogenic role in essential hypertension and the class effect of ACE inhibitors on prostaglandin metabolism. Blood Press 1999; 8:279-284.
42. Johnson AG. NSAIDs and increased blood pressure. What is the clinical significance? Drug Saf 1997; 17:277-289.
43. Morgan T, Anderson A. The effect of nonsteroidal antiinflammatory drugs on blood pressure in patients treated with different antihypertensive drugs. J Clin Hypertens (Greenwich) 2003; 5:53-57.
44. Izhar M, Alausa T, Folker A, Hung E, Bakris GL. Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and Hispanics. Hypertension 2004; 43:573-577.
45. Nawarskas JJ, Townsend RR, Cirigliano MD, Spinler SA. Effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan. Am J Hypertens 1999; 12:784-789.
46. Zanchetti A, Hansson L, Leonetti G, Rahn KH, Ruilope L, Warnold I, Wedel H. Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy. J Hypertens 2002; 20:1015-1022.
47. Cleland JG, John J, Houghton T. Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors in hypertension or heart failure? Curr Opin Nephrol Hypertens 2001; 10:625-631.
48. Lang CC, Stein CM, He HB, Wood AJ. Angiotensin converting enzyme inhibition and sympathetic activity in healthy subjects. Clin Pharmacol Ther 1996; 59:668-674.
49. Ranadive SA, Chen AX, Serajuddin AT. Relative lipophilicities and structural-pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors. Pharm Res 1992; 9:1480-1486.
50. Fagard R, Amery A, Reybrouck T, Lijnen P, Billiet L. Acute and chronic systemic and hemodynamic effects of angiotensin converting enzyme inhibition with captopril in hypertensive patients. Am J Cardiol 1980; 46:295-300.
51. Slavachevsky I, Rachmani R, Levi Z, Brosh D, Lidar M, Ravid M. Effect of enalapril and nifedipine on orthostatic hypotension in older hypertensive patients. J Am Geriatr Soc 2000; 48:807-810.
52. Vanhoutte PM. Endothelial dysfunction and inhibition of converting enzyme. Eur Heart J 1998; 19(suppl J):J7-J15.
53. Schiffrin EL. Effects of antihypertensive drugs on vascular remodeling: do they predict outcome in response to antihypertensive therapy? Curr Opin Nephrol Hypertens 2001; 10:617-624.
54. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252.
55. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
56. Khan NA, McAlister FA, Campbell NR, Feldman RD, Rabkin S, Mahon J, Lewanczuk R, Zarnke KB, Hemmelgarn B, Lebel M, Levine M, Herbert C. Canadian Hypertension Education Program. The 2004 Canadian recommendations for the management of hypertension:Part II-Therapy. Can J Cardiol 2004; 20:41-54.
57. Wing LM, Brown MA, Beilin LJ, Ryan P, Reid CM. ANBP2 Management Committee and Investigators. Second Autralian National Blood Pressure Study. A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2002; 348:583-592.
58. The ALLHAT Officers and Co-ordinators for the ALLHAT Collaborative Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc 2002; 288:1981-1997.
59. Pescatello LS, Franklin BA, Fagard R, Farquhar WB, Kelley GA, Ray CA; American College of Sports Medicine. Exercise and hypertension. Med Sci Sports Exerc 2004; 36:533-553.
60. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328:914-921.
61. Li X, Du Y, Du Y, Huang X. Correlation of angiotensinconverting enzyme gene polymorphism with effect of antihypertensive therapy by angiotensin-converting enzyme inhibitor. J Cardiovasc Pharmacol Ther 2003; 8:25-30.
62. Smith RD, Franklin SS. Comparison of effects of enalapril plus hydrochlorothiazide versus standard triple therapy on renal function in renovascular hypertension. Am J Med 1985; 79(suppl 3C):14-23.
63. Soffer B, Zhang Z, Miller K, Vogt BA, Shahinfar S. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens 2003; 16:795-800.
64. Mokwe E, Ohmit SE, Nasser SA, Shafi T, Saunders E, Crook E, Dudley A, Flack JM. Determinants of blood pressure response to quinapril in black and white hypertensive patients. Hypertension 2004; 43:1-6.
65. Seghal AR. Overlap between whites and blacks in response to antihypertensive drugs. Hypertension 2004; 43:566-572.
66. Weidmann P, De Myttenaere-Bursztein S, Maxwell MH. Effect of aging on plasma renin and aldosterone in normal man. Kidney Int 1975; 8:325-333.
67. Israili ZH, Hall WD. ACE Inhibitors: differential use in elderly patients with hypertension. Drugs Aging 1995; 7:355-371.
68. Omboni S, Fogari R, Palatini P, Rappelli A, Mancia G. Reproducibility and clinical value of the troughto- peak ratio of the antihypertensive effect. Evidence from the sample study. Hypertension 1998; 32:424-429.
69. Morgan TO, Morgan O, Anderson A. Effect of dose on trough peak ratio of antihypertensive drugs in elderly hypertensive males. Clin Exp Pharmacol Physiol 1995; 22:778-780.
70. Sica DA, Gehr TWB. Dose-response relationship and dose adjustments. In: Izzo JL, Black HR, eds. Hypertension Primer. 2nd ed. Baltimore, Maryland: Lippincott Williams & Wilkins, 1999:342-344.
71. Elung-Jensen T, Heisterberg J, Kamper AL, Sonne J, Strandgaard S. Blood pressure response to conventional and low-dose enalapril in chronic renal failure. Br J Clin Pharmacol 2003; 55:139-146.
72. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002; 62:443-462.
73. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Brit Med J 2003; 326:427-434.
74. Docherty A, Dunn FG. Treatment of hypertensive patients with coexisting coronary arterial disease. Curr Opin Cardiol 2003; 18:268-271.
75. Black HR, Sollins JS, Garofalo JL. The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications:a randomized, placebo-controlled study. Am J Hypertens 2000; 13:468-474.
76. Gradman AH, Cutler NR, Davis PJ, Robbins JA, Weiss RJ, Wood BC. Combined enalapril and felodipine extended release for systemic hypertension. Enalapril-Felodipine ER Factorial Study Group. Am J Cardiol 1997; 79:431-435.
77. DeQuattro V, Lee D. Fixed-dose combination therapy with trandolapril and verapamil SR is effective in primary hypertension. Am J Hypertens 1997; 10(suppl 2):138S-145S.
78. Pool J, Kaihlanen P, Lewis G, Ginsberg D, Oparil S, Glazer R, Messerli FH. Once-daily treatment of patients with hypertension: a placebo-controlled study of amlodipine and benazepril vs amlodipine or benazepril alone. J Hum Hypertens 2001; 15:495-498.
79. Neutel JM, Smith DH, Weber MA. Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass. Am J Hypertens 2004; 17:37-42.
80. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW; INVEST Investigators. A calcium antagonist vs a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. J Am Med Assoc 2003; 290:2805-2816.
81. Sica DA. Calcium-channel blocker edema: can it be resolved? J Clin Hypertens 2003; 5:291-294.
82. Zuccala G, Onder G, Pedone C, Cesari M, Marzetti E, Cocchi A, Carbonin P, Bernabei R. Use of calcium antagonists and worsening renal function in patients receiving angiotensin-converting-enzyme inhibitors. Eur J Clin Pharmacol 2003; 58:695-699.
83. Sica DA. Combination angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy: its role in clinical practice. practical aspects of combination therapy with angiotensin-receptor blockers and angiotensin- converting enzyme inhibitors. J Clin Hypertens 2003; 5:414-420.
84. Taylor AA. Is there a place for combining angiotensinconverting enzyme inhibitors and angiotensin-receptor antagonists in the treatment of hypertension, renal disease or congestive heart failure? Curr Opin Nephrol Hypertens 2001; 10:643-648.
85. Pogatsa-Murray G, Varga L, Varga A, Abraham G, Nagy I, Forster T, Csanady M, Sonkodi S. Changes in left ventricular mass during treatment with minoxidil and cilazapril in hypertensive patients with left ventricular hypertrophy. J Hum Hypertens 1997; 11:149-156.
86. Hirschl MM, Binder M, Bur A, Herkner H, Brunner M, Mullner M, Sterz F, Laggner AN. Clinical evaluation of different doses of intravenous enalaprilat in patients with hypertensive crises. Arch Intern Med 1995; 155:2217-2223.
87. Sica DA. Dosage considerations with perindopril for hypertension. Am J Cardiol 2001; 88(suppl 1):13-18.
88. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ. For the VA Cooperative Study Group on Antihypertensive Agents: Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension. Comparison of six antihypertensive agents. Circulation 1997; 95:2007-2014.
89. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114:345-352.
90. Pepine CJ, Rouleau JL, Annis K, Ducharme A, Ma P, Lenis J, Davies R, Thadani U, Chaitman B, Haber HE, Freedman SB, Pressler ML, Pitt B, QUASAR Study Group. Effects of angiotensin-converting enzyme inhibition on transient ischemia: the Quinapril Anti-Ischemia and Symptoms of Angina Reduction (QUASAR) trial. J Am Coll Cardiol 2003; 42:2049-2059.
91. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362:782-788.
92. Daly P, Mettauer B, Rouleau JL, Cousineau D, Burgess JH. Lack of reflex increase in myocardial sympathetic tone after captopril: potential antianginal mechanism. Circulation 1985; 71:317-325.
93. Silber JH, Cnaan A, Clark BJ, Paridon SM, Chin AJ, Rychik J, Hogarty AN, Cohen MI, Barber G, Rutkowski M, Kimball TR, Delaat C, Steinherz LJ, Zhao H. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004; 22:820-828.
94. Chockalingam A, Venkatesan S, Subramaniam T, Jagannathan V, Elangovan S, Alagesan R, Gnanavelu G, Dorairajan S, Krishna BP, Chockalingam V; Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis. Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis:Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis (SCOPE-AS). Am Heart J 2004; 147:E19.
95. Morgan T, Anderson AI, MacInnis RJ. ACE inhibitors, β-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens 2001; 14:241-247.
96. Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004; 17:118-123.
97. Schiffrin EL. Effect of antihypertensive treatment on small artery remodeling in hypertension. Can J Physiol Pharmacol 2003; 81:168-176.
98. Walters MR, Bolster A, Dyker AG, Lees KR. Effect of perindopril on cerebral and renal perfusion in stroke patients with carotid disease. Stroke 2001; 32:473-478.
99. Regensteiner JG, Hiatt WR. Current medical therapies for patients with peripheral arterial disease: a critical review. Am J Med 2002; 112:49-57.
100. Ostergren J, Sleight P, Dagenais G, Danisa K, Bosch J, Qilong Y, Yusuf S; HOPE study investigators. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004; 25:17-24.
101. Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Int Med 2003; 138:593-602.
102. Position Statement. Hypertension management in adults with diabetes. Diabetes Care 2004; 27:S65-S67.
103. Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, Rogulja-Pepeonik Z, Fuller JH. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998; 351:28-31.
104. Sjolie AK, Chaturvedi N. The retinal renin-angiotensin system: implications for therapy in diabetic retinopathy. J Hum Hypertens 2002; 16(suppl 3):S42-S46.
105. Douketis JD, Sharma AM. The management of hypertension in the overweight and obese patient: is weight reduction sufficient? Drugs 2004; 64:795-803.
106. Lithell HO, Pollare T, Berne C. Insulin sensitivity in newly detected hypertensive patients: influence of captopril and other antihypertensive agents on insulin sensitivity and related biological parameters. J Cardiovasc Pharmacol 1990; 15(suppl 5):S46-S52.
107. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, Zinman B; HOPE Study Investigators. Ramipril and the development of diabetes. J Am Med Assoc 2001; 286:1882-1885.
108. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353:611-616.
109. Chuahirun T, Simoni J, Hudson C, Seipel T, Khanna A, Harrist RB, Wesson DE. Cigarette smoking exacerbates and its cessation ameliorates renal injury in type 2 diabetes. Am J Med Sci 2004; 327:57-67.
110. Wright JT Jr, Agodoa L, Contreras G, Greene T, Douglas JG, Lash J, Randall O, Rogers N, Smith MC, Massry S, African American Study of Kidney Disease and Hypertension Study Group. Successful blood pressure control in the African American study of kidney disease and hypertension. Arch Intern Med 2002; 162:1636-1643.
111. Yu HT. Progression of chronic renal failure. Arch Intern Med 2003; 163:1417-1429.
112. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Okin PM, Omvik P, Oparil S, Wedel H, Snapinn SM, Aurup P. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy:the LIFE study. Ann Intern Med 2003; 139:901-906.
113. Donnelly R, Yeung JM, Manning G. Microalbuminuria: a common, independent cardiovascular risk factor, especially but not exclusively in type 2 diabetes. J Hypertens 2003; 21(suppl 1):S7-S12.
114. Brown WW, Peters RM, Ohmit SE, Keane WF, Collins A, Chen SC, King K, Klag MJ, Molony DA, Flack JM. Early detection of kidney disease in community settings: the kidney early evaluation program (KEEP). Am J Kidney Dis 2003; 42:22-35.
115. Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR. Screening for proteinuria in US adults: a cost-effectiveness analysis. J Am Med Assoc 2003; 290:3101-3114.
116. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS; AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139:244-252.
117. Laverman GD, Remuzzi G, Ruggenenti P. ACE inhibition versus angiotensin receptor blockade: which is better for renal and cardiovascular protection? J Am Soc Nephrol 2004; 15(suppl 1):S64-S70.
118. Laverman GD, de Zeeuw D, Navis G. Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy? J Renin Angiotensin Aldosterone Syst 2002; 3:205-213.
119. Campbell R, Sangalli F, Perticucci E, Aros C, Viscarra C, Perna A, Remuzzi A, Bertocchi F, Fagiani L, Remuzzi G, Ruggenenti P. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 2003; 63:1094-1103.
120. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin converting enzyme inhibition in non-insulin dependent diabetes mellitu. A 7-year follow-up study. Arch Int Med 1996; 156:286-289.
121. Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica DA, Broadstone V, Schwartz SL, Mengel MC, Segal R, Versaggi JA. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int Suppl 1994; 45:S150-S155.
122. Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria:European Microalbuminuria Captopril Study Group. J Am Med Assoc 1994; 271:275-279.
123. Ihle BU, Whitworth JA, Shahinfar S, Cnaan A, Kincaid-Smith PS, Becker GJ. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency:a controlled double-blind trial. Am J Kidney Dis 1996; 27:489-495.
124. Giatras I, Lau J, Levey AS. For the Angiotensin-Converting Enzyme Inhibition and Progressive Renal Disease Study Group: Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Ann Intern Med 1997; 127:337-347.
125. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER III, Norris K, O’Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT Jr, Xu S; African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. J Am Med Assoc 2001; 285:2719-2728.
126. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361:117-124.
127. Wilmer WA, Hebert LA, Lewis EJ, Rohde RD, Whittier F, Cattran D, Levey AS, Lewis JB, Spitalewitz S, Blumenthal S, Bain RP. Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the captopril study. Am J Kidney Dis 1999; 34:308-314.
128. Lewis JB, Berl T, Bain RP, Rohde RD, Lewis EJ. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Am J Kidney Dis 1999; 34:809-817.
129. Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61:1086-1097.
130. Estacio R, Jeffers R, Gifford N, Schrier R. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23:B54-B64.
131. Griffin KA, Abu-Amarah I, Picken M, Bidani AK. Renoprotection by ACE inhibition or aldosterone blockade is blood pressure-dependent. Hypertension 2003; 41:201-206.
132. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, de Jong PE, de Zeeuw D, Lau J, Levey AS. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135:73-87.
133. Ruggenenti P, Perna A, Gherardi G, Benini R, Remuzzi G. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 2000; 35:1155-1165.
134. Sica DA. Kinetics of angiotensin converting enzyme inhibitors in renal failure. J Cardiovasc Pharmacol 1992; 20(supp 10):S13-S20.
135. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, de Jong PE, de Zeeuw D, Shahinfar S, Ruggenenti P, Remuzzi G, Levey AS; AIPRD Study Group. Angiotensin-Converting Enzymne Inhibition and Progression of Renal Disease. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001; 60:1131-1140.
136. Marre M, Lievre M, Chatellier G, Mann JF, Passa P, Menard J; DIABHYCAR Study Investigators. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). Brit Med J 2004; 328:495.
137. Mann JF, Gerstein HC, Yi QL, Lonn EM, Hoogwerf BJ, Rashkow A, Yusuf S. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol 2003; 14:641-647.
138. Laverman G, Ruggenenti P, Remuzzi G. Angiotensinconverting enzyme inhibition or angiotensin receptor blockade in hypertensive diabetics? Curr Hypertens Rep 2003; 5:364-367.
139. Ruggenenti P, Mise N, Pisoni R, Arnoldi F, Pezzotta A, Perna A, Cattaneo D, Remuzzi G. Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. Circulation 2003; 107:586-592.
140. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160:685-693.
141. Apperloo AJ, de Zeeuw D, de Jong PE. A short-term antihypertensive- treatment induced drop in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 1997; 51:793-797.
142. Sica DA. Assessment of the role of ACE inhibitors in the elderly. In: Prisant M, ed. Hypertension in the Elderly. Humana Press Inc., 2004. In Press.
143. Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril Kidney Int 1989; 36:272-279.
144. Buter H, Hemmelder MH, Navis G, de Jong PE, de Zeeuw D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998; 13:1682-1685.
145. Gansevoort RT, de Zeeuw D, de Jong PE. Additive antiproteinuric effect of ACE inhibition and a low protein diet in human renal disease. Nephrol Dial Transplant 1995; 10:497-504.
146. Buter H, Hemmelder MH, van Paassen P, Navis G, de Zeeuw D, de Jong PE. Is the antiproteinuric response to inhibition of the renin-angiotensin system less effective during the night? Nephrol Dial Transplant 1997; 12(suppl 2):53-56.
147. Ueda S, Elliott HL, Morton JJ, Connell JM. Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotensin-converting enzyme. Hypertension 1995; 25:1266-1269.
148. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359:641-644.
149. Parving HH, Jacobsen P, Tarnow L, Rossing P, Lecerf L, Poirier O, Cambien F. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme. Observational follow-up study. Brit Med J 1996; 313:591-594.
150. Rudnicki M, Mayer G. Pharmacogenomics of angiotensin converting enzyme inhibitors in renal disease-pathophysiological considerations. Pharmacogenomics 2003; 4:153-162.
151. Garg R, Yusuf S. For the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin- converting enzyme inhibitors on mortality and morbidity in patients with heart failure. J Am Med Assoc 1995; 273:1450-1456.
152. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moye L, Braunwald E. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355:1575-1581.
153. Burwen DR, Galusha DH, Lewis JM, Bedinger MR, Radford MJ, Krumholz HM, Foody JM. National and state trends in quality of care for acute myocardial infarction between 1994-1995 and 1998-1999: the medicare health care quality improvement program. Arch Intern Med 2003; 163:1430-1439.
154. Megarry SG, Sapsford R, Hall AS, Ball SG. Do ACE inhibitors provide protection for the heart in the clinical setting of acute myocardial infarction? Drugs 1997; 54(suppl 5):48-58.
155. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic review of individual data from 100,000 patients in randomised trials. Circulation 1998; 97:2202-2212.
156. Mathew JP, Fontes ML, Tudor IC, Ramsay J, Duke P, Mazer CD, Barash PG, Hsu PH, Mangano DT; Investigators of the Ischemia Research and Education Foundation;Multicenter Study of Perioperative Ischemia Research Group. A multicenter risk index for atrial fibrillation after cardiac surgery. J Am Med Assoc 2004; 291:1720-1729.
157. Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M, Rhodes S, Barrett M, Fonarow GC, Greenberg B, Heidenreich PA, Knabel T, Konstam MA, Steimle A, Warner Stevenson L. Efficacy of ACE inhibitors and β-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41:1529-1538.
158. Liu P, Arnold JM, Belenkie I, Demers C, Dorian P, Gianetti N, Haddad H, Howlett J, Ignazewski A, Jong P, McKelvie R, Moe G, Parker JD, Rao V, Rouleau JL, Teo K, Tsuyuki R, White M, Huckel V, Issac D, Johnstone D, LeBlanc MH, Lee H, Newton G, Niznick J, Ross H, Roth S, Roy D, Smith S, Sussex B, Yusuf S; Canadian Cardiovascular Society. The 2002/3 Canadian Cardiovascular Society consensus guideline update for the diagnosis and management of heart failure. Can J Cardiol 2003; 19:347-356.
159. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary-A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2001; 104:2996-3007.
160. Massie B. Neurohormonal blockade in chronic heart failure; How much is enough? can there be too much? J Am Coll Cardiol 2002; 39:79-82.
161. Remme WJ. Effect of ACE inhibition on neurohormones. Eur Heart J 1998; 19(suppl J):J16-J23.
162. Cruden NL, Witherow FN, Webb DJ, Fox KA, Newby DE. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzymeinhibition in patients with heart failure. Arterioscler Thromb Vasc Biol 2004; 24(suppl 6):1043-1048 (Epub 2004 Apr 22).
163. Anker SD, Negassa A, Coats AJ, Afzal R, Poole-Wilson PA, Cohn JN, Yusuf S. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 2003; 361:1077-1083.
164. Hirooka K, Koretsune Y, Yoshimoto S, Irino H, Abe H, Yasuoka Y, Yamamoto H, Hashimoto K, Chin W, Kusuoka H. Twice-daily administration of a long-acting angiotensin-converting enzyme inhibitor has greater effects on neurohumoral factors than a once-daily regimen in patients with chronic congestive heart failure. J Cardiovasc Pharmacol 2004; 43:56-60.
165. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 2001; 104:1985-1991.
166. Kittleson M, Hurwitz S, Shah MR, Nohria A, Lewis E, Givertz M, Fang J, Jarcho J, Mudge G, Stevenson LW. Development of circulatory-renal limitations to angiotensin- converting enzyme inhibitors identifies patients with severe heart failure and early mortality. J Am Coll Cardiol 2003; 41:2029-2035.
167. Agusti A, Bonet S, Arnau JM, Vidal X, Laporte JR. Adverse effects of ACE inhibitors in patients with chronic heart failure and/or ventricular dysfunction: meta-analysis of randomised clinical trials. Drug Saf 2003; 26:895-908.
168. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349:1893-1906.
169. Bungard TJ, McAlister FA, Johnson JA, Tsuyuki RT. Underutilization of ACE inhibitors in patients with congestive heart failure. Drugs 2001; 61:2021-2033.
170. Chen YT, Wang Y, Radford MJ, Krumholz HM. Angiotensin-converting enzyme inhibitor dosages in elderly patients with heart failure. Am Heart J 2001; 141:410-417.
171. Kvan E, Reikvam A. The problem of underdosing of angiotensin-converting enzyme inhibitors is markedly overrated: results from a study of patients discharged from hospital after an acute myocardial infarction. Eur J Clin Pharmacol 2004; 60:205-210.
172. Schwartz JS, Wang YR, Cleland JG, Gao L, Weiner M, Poole-Wilson PA; ATLAS Study Group. High- versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: an economic analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial. Am J Manag Care 2003; 9:417-424.
173. Dries DJ, Yancy CW, Strong MA, Drazner MH. Racial response to angiotensin-converting enzyme therapy in systolic heart failure. Cong Heart Fail 2004; 10:30-33.
174. Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, Rapaport E, Riegel B, Russell RO, Smith EE III, Weaver WD, Gibbons RJ, Alpert JS, Eagle KA, Gardner TJ, Garson A Jr, Gregoratos G, Smith SC Jr. 1999 update: ACC/AHA Guidelines for the Management of Patients with Acute Myocardial Infarction: Executive Summary and Recommendations: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1999; 100:1016-1030.
175. Naccarella F, Naccarelli GV, Maranga SS, Lepera G, Grippo MC, Melandri F, Gatti M, Pazzaglia S, Spinelli G, Angelini V, Ambrosioni E, Borghi C, Giovagnorio MT, Nisam S. Do ACE inhibitors or angiotensin II antagonists reduce total mortality and arrhythmic mortality? A critical review of controlled clinical trials. Curr Opin Cardiol 2002; 17:6-18.
176. Turnbull F; Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressurelowering regimens on major cardiovascular events:results of prospectively-designed overviews of randomised trials. Lancet 2003; 362:1527-1535.
177. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033-1041.
178. Anderson C. Blood pressure-lowering for secondary prevention of stroke: ACE inhibition is the key. Stroke 2003; 34:1333-1334.
179. Bath P. Blood pressure-lowering for secondary prevention of stroke: ACE inhibition is not the key. Stroke 2003; 34:1334-1335.
180. Davis SM, Donnan GA. Blood pressure reduction and ACE inhibition in secondary stroke prevention: mechanism uncertain. Stroke 2003; 34:1335-1336.
181. Fournier A, Messerli FH, Achard JM, Fernandez L. Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol 2004; 43:1343-1347.
182. Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, Davies R, Ostergren J, Probstfield J; HOPE Investigators. Heart outcomes prevention evaluation. Use of ramipril in preventing stroke: double blind randomised trial. Brit Med J 2002; 324:699-702.
183. Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G, Hill M, Howard G, Howard VJ, Jacobs B, Levine SR, Mosca L, Sacco RL, Sherman DG, Wolf PA, del Zoppo GJ. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 2001; 32:280-299.
184. Ohkubo T, Chapman N, Neal B, Woodward M, Omae T, Chalmers J; Perindopril Protection Against Recurrent Stroke Sutdy Collaborative Group. Effects of an angiotensin- converting enzyme inhibitor-based regimen on pneumonia risk. Am J Respir Crit Care Med 2004; 169:1041-1045.
185. Arai T, Yasuda Y, Takaya T, Toshima S, Kashiki Y, Shibayama M, Yoshimi N, Fujiwara H. Angiotensinconverting enzyme inhibitors, angiotensin-II receptor antagonists, and pneumonia in elderly hypertensive patients with stroke. Chest 2001; 119:660-661.
186. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, Chalmers J; PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003; 163:1069-1075.
187. Textor SC. Renal failure related to angiotensin-converting enzyme inhibitors. Semin Nephrol 1997; 17:67-76.
188. Bouvy ML, Heerdink ER, Hoes AW, Leufkens HG. Effects of NSAIDs on the incidence of hospitalisations for renal dysfunction in users of ACE inhibitors. Drug Saf 2003; 26:983-989.
189. Tabacova S, Little R, Tsong Y, Vega A, Kimmel CA. Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment. Pharmacoepidemiol Drug Saf 2003; 12:633-646.
190. Textor SC, Bravo EL, Fouad FM, Tarazi RC. Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril. Am J Med 1982; 73:719-725.
191. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-drug interactions among elderly patients hospitalized for drug toxicity. J Am Med Assoc 2003; 289:1652-1658.
192. Cruz CS, Cruz AA, Marcilio de Souza CA. Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone. Nephrol Dial Transplant 2003; 18:1814-1819.
193. Israili ZH, Hall WD. Cough and angioneurotic associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann Intern Med 1992; 117:234-242.
194. Chalmers D, Dombey SL, Lawson DH. Post-marketing surveillance of captopril (for hypertension): a preliminary report. Br J Clin Pharmacol 1987; 24:343-349.
195. Rahimtoola H, Buurma H, Tijssen CC, Leufkens HG, Egberts AC. Reduction in the therapeutic intensity of abortive migraine drug use during ACE inhibition therapy-a pilot study. Pharmacoepidemiol Drug Saf 2004; 13:41-47.
196. Onder G, Pahor M, Gambassi G, Federici A, Savo A, Carbonin P, Bernabei R, GIFA Study. Association between ACE inhibitors use and headache caused by nitrates among hypertensive patients: results from the Italian group of pharmacoepidemiology in the elderly. Cephalalgia 2003; 23:901-906.
197. Gibbs CR, Lip GYH, Beevers DG. Angioedema due to ACE inhibitors: increased risk in patients of African origin. Br J Clin Pharmacol 1999; 48:861-865.
198. Cicardi M, Zingale LC, Bergamaschini L, Agostoni A. Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch Int Med 2004; 164:910-913.
199. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensinconverting enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362:772-776.
200. Gregory KW, Davis RC. Images in clinical medicine. Angioedema of the intestine.NEngl JMed 1996; 334:1641.
201. Orr KK, Myers JR. Intermittent visceral edema induced by long-term enalapril administration. Ann Pharmacother 2004; 38:825-827.
202. Cheng RM, Mamdani M, Jackevicius CA, Tu K. Association between ACE inhibitors and acute pancreatitis in the elderly. Ann Pharmacother 2003; 37:994-998.
203. Sica DA, Gehr TWB. The pharmacokinetics and pharmacodynamics of angiotensin receptor blockers in end-stage renal disease. J Renin-Angio Aldo Sys 2002; 3:247-254.
204. Rasoul S, Carretero OA, Peng H, Cavasin MA, Zhuo J, Sanchez-Mendoza A, Brigstock DR, Rhaleb NE. Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension. J Hypertens 2004; 22:593-603.
205. Yildiz A, Cine N, Akkaya V, Sahin S, Ismailoglu V, Turk S, Bozfakioglu S, Sever MS. Comparison of the effects of enalapril and losartan on posttransplantation erythrocytosis in renal transplant recipients: prospective randomized study. Transplantation 2001; 72:542-545.
206. Trivedi H, Lal SM. A prospective, randomized, open labeled crossover trial of fosinopril and theophylline in post renal transplant erythrocytosis. Ren Fail 2003; 25:77-86.
207. Plata R, Cornejo A, Arratia C, Anabaya A, Perna A, Dimitrov BD, Remuzzi G, Ruggenenti P, Commission on Global Advancement of Nephrology (COMGAN), Research Subcommittee of the International Society of Nephrology. Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trial. Lancet 2002; 359:663-666.